PARK7 and hepatocellular carcinoma: Therefore, it is reasonable to suspect that the DJ-1/FGFR1 signaling pathway might contribute to sorafenib resistance in HCC, and the inhibition of DJ-1/FGFR1 pathway will benefit a subset of sorafenib resistant patients with high expression of DJ-1.